Eisai Presents New Data Analyses on Fycompa® (Perampanel) at American Epilepsy Society Annual Meeting

Eisai Presents New Data Analyses onEisai Presents New Data Analyses on Fycompa® (Perampanel) at American Epilepsy Society Annual Meeting PR Newswire HATFIELD, England, December 6, 2013 Eisai today announced that 16 abstracts highlighting new data analyses ®on Fycompa (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting in Washington, D.C. between 6- 10 December. Perampanel is indicated in the European Union (EU) for the adjunctive treatment of partial-onset seizures, with or without secondarily [1]generalised seizures, in patients with epilepsy aged 12 years and older. "These data analyses highlight Eisai's clinical research with Fycompa and reinforce our commitment to the epilepsy community," commented Lynn Kramer, MD, President of the Neuroscience and General Medicine Product Creation Unit and Chief Clinical Officer of Eisai Product Creation Systems, Eisai's research and development organisation. The following abstracts regarding perampanel will be presented at this year's AES Meeting: Abstract Number Abstract Name Assessment of Liver Toxicity in Perampanel-Treated 1.